Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease
about
p25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathiesProtein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseasesDefinition of a molecular pathway mediating α-synuclein neurotoxicityExploring the accessible conformations of N-terminal acetylated α-synucleinThe phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's diseaseMicrotubule-associated protein 1B is a component of cortical Lewy bodies and binds alpha-synuclein filamentsProtein-metal interactions of calmodulin and alpha-synuclein monitored by selective noncovalent adduct protein probing mass spectrometry.Aberrant protein structure and diseases of the brain.At low concentrations, 3,4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to alpha-synuclein and prevents its fibrillationNigrostriatal neuronal death following chronic dichlorvos exposure: crosstalk between mitochondrial impairments, α synuclein aggregation, oxidative damage and behavioral changesBiochemical characterization of the core structure of alpha-synuclein filaments.Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopyMultiple system atrophy: a sporadic synucleinopathy.Neuropathology of synuclein aggregates.Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson's diseaseStructure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicityBaicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism.Distinct hydration properties of wild-type and familial point mutant A53T of α-synuclein associated with Parkinson's disease.Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins.Familial conformational diseases and dementias.Parkinson's disease and other alpha-synucleinopathies.Identification of a helical intermediate in trifluoroethanol-induced alpha-synuclein aggregationalpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease.Protein aggregates and dementia: is there a common toxicity?Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.Genetics of parkinsonism.Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease.Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.The many faces of α-synuclein: from structure and toxicity to therapeutic target.Parkinson disease mutant E46K enhances α-synuclein phosphorylation in mammalian cell lines, in yeast, and in vivoThe crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy.Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformationSelective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse modelGenetics of neurological disorders.Structures and free energy landscapes of the wild-type and A30P mutant-type α-synuclein proteins with dynamics.Using leucine zipper to facilitate alpha-synuclein assembly.Progress in the pathogenesis and genetics of Parkinson's disease.Stressing Out Hsp90 in Neurotoxic Proteinopathies.
P2860
Q24320549-03D952AC-D0E7-4ABC-96E6-E1F673EED5BDQ24650014-15FD3842-EF31-49D0-AF4D-37C951428019Q26269832-A7A94365-D9B8-495B-A805-70ACC8CFB9E6Q26852660-8A33CE53-5590-48DF-80CB-6318B609B80EQ28087330-04AB9E69-F6FD-4F23-A487-5973E2B9D37BQ28141728-DD77044B-96B6-4A45-8E7B-84E6C461EC78Q30371293-3C2C4212-DBF8-4776-9E4F-5E6FC2E621A0Q30395060-5ED84F9B-3320-4BB7-A408-86DAF663F901Q30481562-B770CEF1-698D-451B-9286-0CEF36FDDB1FQ30497542-82E5A188-C4A6-4022-8E95-6DAA9D160CDFQ30827075-782A126C-4B83-45F9-975B-0038672A32A5Q33470625-C0632D4C-C0F8-48C8-83AC-99CC853F977BQ33627226-45AA3EA0-B0B2-4B78-B02F-E0B0424D1CE8Q33750069-931BD521-560E-4D4E-8A43-931E4945879FQ33957376-5D3A141F-C417-475B-B423-C48350520AAEQ33980640-508408B8-1934-4361-987A-7BF463026BB8Q34003885-B0303618-391E-44FB-BB33-59A32F005228Q34020622-AAE71A5B-14A8-4722-8873-EF45D1A826ABQ34070003-0AC0417F-36F3-484A-BD9B-3F8BF8793D2DQ34111411-EF7C0BEF-A87D-4448-9FCD-EAD968C94B05Q34138249-FC34E583-6F46-4849-8FF4-CE5C7030E53DQ34270992-2FF631AE-DE43-4207-B203-306ABCEF3E3CQ34279026-C7A4488B-3695-4953-A530-6AB2C33E5216Q34319713-5AAFABD3-4788-40E9-B4F0-5E108B654228Q34498308-DFA0DBF3-3697-4A4C-96D1-F367C7AADFC9Q34648491-6FBA881C-EF2D-43DD-8004-64E3BC005519Q34763209-4CF4811E-5897-4595-A774-AC39E6589587Q34811944-F62DD2E1-9C9B-4152-90F2-F23F45675348Q34917354-C16A8181-4B88-41A1-8E78-74173954A482Q34964783-08D0D514-E6B2-4DAC-ABEB-DECE141E21A1Q34972009-765778D7-1D1F-465C-9510-6724C0D01709Q35351512-B44D6B26-73A9-4042-B7B0-5DC794FE5BBEQ35545150-EE6BF980-C6FE-4F6F-9B2C-A639FAB77B24Q35700288-54153632-CC9B-4EF9-B2BD-38A9C898127EQ35747138-2EDDB192-4DC0-40F9-982C-73F4C90447B7Q35770559-A52B62FF-ED83-4C26-B696-0656AF1F96D0Q36713739-5B279981-F7FD-46AB-BD13-7DF008B8C635Q36841771-7903CC0F-D158-4CB0-A2A6-E06225C2074FQ37143657-2D25B3D1-3561-4B7C-9E70-F89E3AC084C4Q37198079-DC329A17-E13A-4315-BECA-5C7DE7A20F2B
P2860
Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease
description
1998 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1998
@ast
im November 1998 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1998/11/27)
@sk
vědecký článek publikovaný v roce 1998
@cs
wetenschappelijk artikel (gepubliceerd op 1998/11/27)
@nl
наукова стаття, опублікована в листопаді 1998
@uk
مقالة علمية (نشرت في 27-11-1998)
@ar
name
Effects of the mutations Ala30 ...... licated in Parkinson's disease
@ast
Effects of the mutations Ala30 ...... licated in Parkinson's disease
@en
Effects of the mutations Ala30 ...... licated in Parkinson's disease
@nl
type
label
Effects of the mutations Ala30 ...... licated in Parkinson's disease
@ast
Effects of the mutations Ala30 ...... licated in Parkinson's disease
@en
Effects of the mutations Ala30 ...... licated in Parkinson's disease
@nl
altLabel
Effects of the mutations Ala30 ...... licated in Parkinson's disease
@en
prefLabel
Effects of the mutations Ala30 ...... licated in Parkinson's disease
@ast
Effects of the mutations Ala30 ...... licated in Parkinson's disease
@en
Effects of the mutations Ala30 ...... licated in Parkinson's disease
@nl
P2093
P2860
P1433
P1476
Effects of the mutations Ala30 ...... licated in Parkinson's disease
@en
P2093
A. Wallace
M. D. Curran
O. M. El-Agnaf
P2860
P356
10.1016/S0014-5793(98)01419-7
P407
P577
1998-11-27T00:00:00Z